OncoCyte Corp (NAS:OCX)
$ 2.435 -0.095 (-3.75%) Market Cap: 40.99 Mil Enterprise Value: 41.62 Mil PE Ratio: 0 PB Ratio: 3.35 GF Score: 31/100

OncoCyte Corp Key Opinion Leader Presentation Part 2: DetermaIO™ in Triple-Negative Breast Cancer Transcript

Sep 28, 2021 / 05:00PM GMT
Release Date Price: $72.2 (-7.67%)
Operator

Presentation Part 2: DetermaIO⢠in Triple-Negative Breast Cancer
Sep 28, 2021 / 05:00PM GMT

=====================
Corporate Participants
=====================
* Robert S. Seitz
OncoCyte Corporation - Head of Immune Oncology
* Ronald A. Andrews
OncoCyte Corporation - CEO, President & Director

=====================
Conference Call Participants
=====================
* Bruce David Jackson
The Benchmark Company, LLC, Research Division - Senior Equity Analyst
* Mark Anthony Massaro
BTIG, LLC, Research Division - MD & Life Science & Diagnostic Tools Analyst
* Michael Stephen Matson
Needham & Company, LLC, Research Division - Senior Analyst
* Thomas Flaten
Lake Street Capital Markets, LLC, Research Division - Senior Research Analyst
* Giampaolo Bianchini
* Priyanka Sharma

=====================

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot